The progress of serialisation in the US and beyond

Published: 9-Feb-2016

Protecting patients from product fraud and tampering has become a major industry and regulatory initiative. Justin Schroeder, Executive Director Marketing, Business Development and Design, PCI Pharma Services, summarises progress and highlights some unresolved issues

You need to be a subscriber to read this article.
Click here to find out more.

For professionals in the healthcare industry, the ultimate mission is to provide life-saving medicines to patients around the world. Critical to that mission is patient safety. Patients around the globe trust that their medicines are both safe and effective. The industry’s unwavering commitment is to ensure that their trust is well placed.

The healthcare industry has often been ‘reactionary’ when it comes to improvements in packaging to ensure patient safety. The most widely known instance of this was in 1982 with deaths relating to adulterated acetaminophen in the United States. The swift industry response is well documented and has become a business school study standard. As a result, tamper-evident features in packaging are now the standard and the typical consumer would be concerned to find them lacking. Common package labelling instructs the patient to look for these features and clearly states to avoid the medication if the features are not present or appear to have been tampered with.

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.

Relevant companies

You may also like